AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Vanguard's Latest US Market ETF Distribution: Key Dates and Details
March 26, 2025 12:00 AM AEDT| By Team Kalkine MediaHighlights,Final distribution announced for (ASX:VTS) holders.,Key dates from ex-distribution to payment detailed.,Important information on CDI cancellation requests.,Vanguard Investments Australia Ltd recently announced a final distribution for the...
ASX Stocks Gaining Attention Amid Market Fluctuations
March 25, 2025 05:56 PM AEDT| By Team Kalkine MediaASX Stocks Gaining Attention Amid Market Fluctuations
Immutep makes progress with first lung cancer patient dosing
March 25, 2025 03:31 PM AEDT| By Team Kalkine MediaImmutep makes progress with first lung cancer patient dosing
Aroa Biosurgery (ARX) Is Well-Positioned for Business Growth
March 25, 2025 03:31 PM AEDT| By Team Kalkine MediaAroa Biosurgery (ARX) Is Well-Positioned for Business Growth
Immutep Limited (ASX:IMM) Launches Major Phase III Trial Targeting Lung Cancer
March 25, 2025 03:06 PM AEDT| By Team Kalkine MediaHighlights,Immutep Limited (IMM) begins pivotal Phase III trial for lung cancer treatment.,The global study aims to enroll over 750 patients in 25+ countries.,Potential for setting a new standard of care in treating advanced lung cancer.,In a signifi...
Is Investing in Ramsay Health Care (RHC) Considered Risky?
March 24, 2025 01:32 PM AEDT| By Team Kalkine MediaIs Investing in Ramsay Health Care (RHC) Considered Risky?
Beamtree Expands Automation in Clinical Coding
March 24, 2025 01:30 PM AEDT| By Team Kalkine MediaBeamtree Expands Automation in Clinical Coding
Opthea's Phase 3 trial results fall short in aiding patients, putting the company's future in jeopardy.
March 24, 2025 01:30 PM AEDT| By Team Kalkine MediaOpthea's Phase 3 trial results fall short in aiding patients, putting the company's future in jeopardy.
Clinical Trials and Technological Innovations: A Mixed Landscape
March 24, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,Opthea's eye disease trial fails to meet primary endpoints, casting doubts on its future.,HitIQ partners with a major Australian amateur league, aiming to improve concussion detection.,Telix receives FDA approval, extending its prostate ca...
Opthea Seeks Lifeline After Clinical Setback, Suspends Trading to Regroup
March 24, 2025 12:00 AM AEDT| By Team Kalkine MediaHighlights,Opthea pauses trading as it explores funding options,Clinical trial for OPT-302 misses key target,Future of wet-AMD treatment strategy under review,Opthea (ASX:OPT) has entered a critical phase in its development journey, as trading of its...
Austco Healthcare's Impressive Growth Journey
March 22, 2025 05:30 PM AEDT| By Team Kalkine MediaHighlights,Austco Healthcare's share price soared 455% over five years.,The company achieved a total shareholder return of 478% over the same period.,Recent insider buying suggests potential confidence in future growth.,Investors have often been on t...
Trajan Group's Innovative Ventures and Global Strategy
March 22, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,Trajan Group's micro blood sampling tools are influencing both terrestrial and space applications, providing precise samples in even the most remote locations.,The company is at the forefront of detecting 'forever chemicals' and impurities...
Institutional Influence and Ownership Structure of Cochlear Limited (COH)
March 21, 2025 07:30 PM AEDT| By Team Kalkine MediaInstitutional Influence and Ownership Structure of Cochlear Limited (COH)
Compumedics Secures $20M in Chinese MEG Sales as Demand for Brain Imaging Tech Rises
March 21, 2025 06:57 PM AEDT| By Team Kalkine MediaHighlights,$20M in MEG system sales achieved in China,Latest $5.7M deal signed with Hangzhou Normal University,Growing momentum signals strong future potential in global neuroimaging market,Compumedics (ASX:CMP), a leading developer of brain research...
Nanosonics Shares Surge After US Approval, But Analysts Urge Caution on Valuation
March 21, 2025 04:42 PM AEDT| By Team Kalkine MediaHighlights,Nanosonics shares jump after US FDA greenlight,CORIS tool sees early investor excitement,Analysts flag slow rollout and valuation concerns,Nanosonics (ASX:NAN) saw a strong rally in its share price following the US Food and Drug Administra...
Can Cochlear (ASX:COH) Regain Momentum in 2025? Here’s What the Numbers Say
March 21, 2025 02:42 PM AEDT| By Team Kalkine MediaHighlights,Revenue growth averaging 14.3% per year over 3 years,Strong gross margin of 74.9% and healthy net profit,Low debt levels and solid return on equity,The share price of Cochlear (ASX:COH), a global leader in hearing solutions, has declined b...
MedAdvisor Limited's (ASX:MDR) Stock Performance: A Deep Dive
March 21, 2025 01:30 PM AEDT| By Team Kalkine MediaHighlights,MedAdvisor Limited (ASX:MDR) has seen a significant stock price drop.,The company’s growth forecasts are lagging behind the industry.,Revenue trends show a mixed performance over recent years.,MedAdvisor Limited (ASX:MDR) has experienced a...
ResMed (ASX:RMD) A Closer Look at Its Market Performance and Growth Potential
March 21, 2025 12:07 PM AEDT| By Team Kalkine MediaHighlights,ResMed’s Market Movement,: Shares of ResMed (RMD) have declined by 4.6% since the start of 2025.,Healthcare Industry Resilience,: The sector is known for its stable revenue streams and growth potential.,Valuation Insights,: Current price-t...
FDA Greenlights Telix’s Advanced Prostate Cancer Imaging Agent, Gozellix®
March 21, 2025 12:05 PM AEDT| By Team Kalkine MediaHighlights,FDA approves,Telix’s,next-gen prostate cancer imaging agent,Gozellix,® offers wider access through extended shelf life,Reimbursement eligibility improves patient reach,Telix Pharmaceuticals Limited (ASX:TLX) has achieved a major regulatory...
Reviving Potential: How Race Oncology’s Breakthrough Could Redefine Cancer Treatment
March 21, 2025 11:37 AM AEDT| By Team Kalkine MediaHighlights,Race Oncology brings back a shelved cancer drug with modern innovation,New formulation offers 20 years of exclusive patent protection,Potential heart-protective benefits in combination chemotherapy,Race Oncology (ASX:RAC) is turning heads...
Advertise your brand on Kalkine Media